UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2026
Commission File Number: 001-42796
Nasus Pharma Ltd.
Yigal Alon 65
Tel Aviv, Israel 6744317
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
On March 4, 2026, Nasus Pharma Ltd. (the “Company”) announced that, due to the security situation in the State of Israel and restrictions on public gatherings, the location of the Company’s Special General Meeting of Shareholders (the “Meeting”) has been changed to a virtual meeting format only.
Shareholders will not be able to attend the Meeting in person. As previously announced by the Company in its Report of Foreign Private Issuer on Form 6-K on January 29, 2026, the Meeting will be held on Thursday, March 5, 2026 at 2:00 p.m. Israel time. Shareholders may attend the Meeting virtually at:
| ● | Link: https://zoom.us/j/94874269962?pwd=OWuiu8uqYLCInuxNe5vRg2w2BiqziZ.1 | |
| ● | Meeting ID: 948 7426 9962 | |
| ● | Passcode: 229406 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NASUS PHARMA LTD. | ||
| Date: March 4, 2026 | By: | /s/ Dan Teleman |
| Name: | Dan Teleman | |
| Title: | Chief Executive Officer | |